Sharma A, Vaduganathan M, Ferreira JP, et al. - In a multicenter, non-inferiority, double-masked, placebo-controlled trial, named EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care), of alogliptin vs placebo following recent acute coronary syndrome in patients with type 2 diabetes mellitus (n = 5,380), researchers investigated clinical as well as biomarker predictors for expanded heart failure (HF) outcomes, given improved HF risk stratification following a recent acute coronary syndrome may recognize candidates for whom HF risk-reducing therapies can be beneficial. There were 5,154 patients, with median age 61.0 years, 67.7% were men. Evaluation of baseline biomarkers such as NT-proBNP (N-terminal pro-B-type natriuretic peptide), high-sensitivity troponin I, adiponectin, growth-differentiation-factor-15, and galectin-3 was done in these individuals. Cardiovascular mortality, HF hospitalization, raised NT-proBNP during follow-up, or loop diuretics initiation was the primary outcome. Experts concluded that risk stratification for expanded HF outcomes in patients with type 2 diabetes mellitus after recent acute coronary syndrome is allowed by the use of biomarkers such as NT-proBNP and clinical variables.